Alpha Cognition Inc
ACOG
Rankning i aktier
#20002
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aktiekurs
$8.63
Senast synkroniserad: 2026-10-21
Marknadsvärde
$134.04M
Förändring (1 dag)
0.23%
Förändring (1 år)
71.57%
Land
US
Handel Alpha Cognition Inc (ACOG)
Kategori
Healthcare
Aktiekurshistorik för Alpha Cognition Inc (ACOG)
Högsta slutkurs: $5.46 den 2024-12-01
Lägsta slutkurs: $18.75 den 2021-06-01
Lägsta slutkurs: $18.75 den 2021-06-01
Aktiekurshistorik för Alpha Cognition Inc från 2021 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2024 | -51.49% |
| 2023 | 87.35% |
| 2022 | -73.46% |
| 2021 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $761.37 | 8.22% |
CH
|
